Expect CLBE to run strong tomorrow and perhaps for the rest of this week. Afterhours press release could not have come at a better time as the chart has been drawing out bullish indicators. Just crossed 50 day ma, and uptrend is definetly in the making here. Positive convergence on MACD and on top of that the MACD is getting ready to make bullish centerline crossover. The revenue increase shows strong future for this Stem Cell research company. I wont be surprised to see this trading in the Nasdaq next year, but for short term, this is a great entry point. Last month this ran up for 6 days straight to .12 on weaker news. Expect similar run if not bigger. I see this solidly trading above .10 in due time. Don't believe me? Watch....
Revision History (2 edits; 1 reasons shown)
DeMerchant - Monday, September 25, 2006, 10:10:16pm
OTC stocks are for trading imo not 'investing'. Professionals Moderator
Posts
1,722
Posts Per Day
1.29
Reputation
73.91%
Time Online
7 days 10 hours 5 minutes
Hey dapper, have you given up on WSBL? I know you were really over the moon on that one when it hit up around 3 or 4 cents in mid September.
Come and join me in "THE SWAMP", the OTC swamp that is. Help me identify which stocks have the postential for BIG GAINS before the industry hacks start pumping and dumping them.
Well, I've traded it maybe 4-5 times since then, all for decent profits. This is a high risk/high reward game, therefore, I apologize if you lost $ on that play. You must really be on your toes to play the pennies, watching the 1,2 and 5 minute charts looking for exit and entry points. I posted ctgle a couple days ago and it's up 40% sice then. Now I'm posting CLBE because I'm confident that it will rally this week. If you would like me to stop posting on this board, please just ask and I will. But one bad post should not devalorize my intuition. CLBE is a solid pick up here. You'll see tomorrow Get in while you can.
CLBE is a great mid-long term investment. They just recently reported a significant increase in revenues for the past 9 months. With another profitable quarter, this one could break out to new trading ranges. This is a not another junky catchpenny. They sell quality products and are engaged in a business that will play a huge roll in stem cell developments these next few years.
Here are some the quotes from their recent 10K:
-"The Company believes that it will report a net profit for 2005.”
-Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
-After the acquisition of KD Medical, the Research Reagents Division has two companies with combined 2004 revenues of approximately $1.2 Million in gross revenues. Within three years, it is anticipated that revenues will grow to $5 Million.
-The Company anticipates the launch of LifeStem's stem cell MicroBank in the first quarter of 2006, which the Company believes will lead to significant additional revenue.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute innovation in areas of biological discovery.
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due to the growth of new cellular therapeutics as well as clinical applications. LifeStem's strategy is to leverage CalbaTech's infrastructure of companies to obtain a leadership position in the emerging stem cells arena and become a preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
The one thing about high quality penny stocks is that they rarely ever run high and fast at the same time. Most are slow growth but strong investments to certain levels. As science progress anyone can see that stem cell technology is going to be a major contributor but many here may believe that is all CalbaTech does and that’s not true. They are really deep into DNA and molecular research also.
CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
Molecula Research Laboratories, LLC
Molecula Research Laboratories, LLC ("Molecula"), located in Sterling, Virginia, is dedicated to meeting the needs of research scientists in the pharmaceutical, biotech, medical and academic research sectors by providing cell and molecular biology reagents and associated consumables. Molecula, a wholly owned subsidiary of the Company, is actively expanding its product range in siRNA. This builds upon its well-established reputation as a designer, manufacturer and supplier of active antisense oligonucleotides.
Molecula is focused on gene function solutions using RNAi technology. Their proprietary computer algorithm - T.A.R.G.E.T.? (The Advanced RNAi Guidance Evaluation Technology) system and 10 years of gene silencing experience, allows Molecula to consistently deliver active RNA duplexes for specific target gene silencing.
Molecula also develops and sells numerous research reagents for cell transfection, DNA and RNA purification, protein expression, gene expression analysis and other innovative and fundamental products. Molecula also sells transfection reagents, a novel IPTG replacement for increased protein expression, neuropeptides and biochemicals. Please see http://www.molecula.com.
KD Medical, Inc
CTI's first acquisition within the research reagent market was Molecula. Molecula has excellent design and manufacturing capabilities and is seeking opportunities to market its products on a larger scale.
After acquiring Molecula, the next step was to establish a more competitive entity capable of comprehensively supplying the specialist media and reagent needs of cell and molecular biology researchers. The product ranges of KD and Molecula are highly complementary, with little overlap. One of KD's greatest strengths is in the supply of specialized media for culture of model research organisms such as bacteria, yeast, insects and mammalian cell lines. It also supplies products to approximately 300 National Institutes of Health ("NIH") laboratories, contracts invaluable for establishing new products in a favorable government setting. Its secondary products are related to molecular biology reagents. Conversely, Molecula's primary focus is in the design and supply of high value molecular biology reagents such as siRNA and DNA antisense oligonucleotides. It also has reagents such as IPTG that are complementary to customized media. A large proportion of such research depends upon culture of a model organism (bacteria, fruit fly, etc.), which is genetically manipulated by transfection of customized oligonucleotides (siRNA). Thus, an alliance of KD and Molecula will be well placed to provide a competitive single source for these culture media transfection reagents and specialized modifier molecules such as siRNA. Further, as explained above, KD's long standing and trusted position, as a major in-house supplier to NIH will greatly ease entry of Molecula's siRNA into that major market. Please see http://www.kdmedical.com.
THE CELLULAR THERAPIES DIVISION
Strategy
The Cellular Therapies Division was created to house CalbaTech's emerging interests in cellular applications, particularly those relating to the use of adult stem cells. The Company believes this is an emerging market in which there are major opportunities for new entrants to establish new standards through novel stem cell research techniques and business models. The Company is positioning itself through strategic alliances to identify and take advantage of such opportunities as they emerge from the interaction between fundamental research and an evolving regulatory environment.
To this end, CalbaTech has incorporated LifeStem, Inc., to take advantage of this rapidly expanding market. In addition to advancing its business model for stem cell banking and the provision of purified stem cells to researchers, CalbaTech has filed a patent application for intellectual property relating to the efficient and effective delivery of stem cells to diseased or dead areas of the heart. This device should allow for effective and efficient delivery of stem cells to heart tissue to promote regeneration post myocardial infarction (heart attack). CalbaTech is currently seeking collaborative partners for this innovative device
LifeStem, Inc.
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 (Source DMD). This is projected due to the growth of new cellular therapeutics based on embryonic and adult stem cells, as well as clinical applications to compete with, or complement, existing drug based therapeutics. LifeStem's strategy is to leverage the CalbaTech infrastructure of companies to obtain a leadership position in the fast emerging stem cells arena and become the preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services. In time, it is anticipated that elements of LifeStem's services will become standard practice in mainstream clinical applications, thus opening a much larger market to LifeStem as a cellular logistics services company.
LifeStem is positioning itself to become a leading supplier of "Cellular Logistics" in this large new market. The company is focused on the following: (1) Providing a stem cell banking service to affluent individuals; (2) Providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market; (3) Developing delivery devices for clinical applications; and (4) Developing clinical applications of specific stem cell based therapies.
Stem Cell Banking
The opportunity to collect and preserve healthy adult stem cells on a pre-disease basis is certain to revolutionize the practice of medicine. The power and promise of stem cell therapies is just beginning to be known but the development of new clinical applications and therapies is imminent.
That link takes you too many other informative press releases and various pr’s. The adult stem cell industry is going to be measured in the hundreds of billions without any doubt. CLBE is linked up with just about all of the major pharmaceutical companies and when you read some of the links you will see why that is so important. These companies are throwing around tens of millions of dollars into stem cell related companies, trust me; they know exactly what they are doing.
The opportunity to collect and preserve healthy adult stem cells on a pre-disease basis is certain to revolutionize the practice of medicine. The power and promise of stem cell therapies is just beginning to be known but the development of new clinical applications and therapies is imminent. http://www.healthcareindustrytoday.com/news/StemCellResearch
That link takes you too many other informative press releases and various pr’s. The adult stem cell industry is going to be measured in the hundreds of billions without any doubt. CLBE is linked up with just about all of the major pharmaceutical companies and when you read some of the links you will see why that is so important. These companies are throwing around tens of millions of dollars into stem cell related companies, trust me; they know exactly what they are doing.
Watch this tomorrow and next week people!! This is ready to bust loosr and touch .05
If it breaks .05, this can go to .10+
Big news coming soon. Dont say I didnt inform you guys in time. Chance of acquiring shares this cheap are dwindling. Under .04 is a bargain IMO. Check out chart..
Up 21% today and closed at high of day, indicating that trend is strong going into next trading session. Im telling you people, DONT WAIT! Buying at any price under .04 will generate profits in 2-3 weeks. Big news is coming and for those holding long, 2006 is going to be a promising year for CLBE. Last time chart looked like this, this ran up to .10
Dont hesitate to buy under a nickle. I'm telling you all now, this is going to bust loose in the near future. Dexterous sharehoders hanging on to their shares. This will touch .10 by 2nd quarter, mark this thread. (Thats over 300% on your return)
Congrats to those that got in when first alerted. Those that were patient enough reaped over a 300% profit and IMO, this only the start of a HUGE rally coming for CLBE. Great week, but BETTER days are coming. MARK THIS THREAD!!
Logged
